Most senior healthcare executives agreed that a healthcare system that embraces transparency will produce safer care and better outcomes, but a minority are happy with the current degree of transparency in their organization.
Most senior healthcare executives (93%) agreed that a healthcare system that embraces transparency will produce safer care and better outcomes, according to the poll results of the National Patient Safety Foundation’s (NPSF) annual Patient Safety Congress. However, only 22% said they were satisfied with the degree of transparency in their organization.
According to the NPSF, making transparency part of routine practice starts with focusing on the relationship between clinicians and patients, and it has developed a series of best practice approaches and educational opportunities specific to Communication and Resolution Programs.
“Transparency is essential if professionals and organizations are to learn from mistakes and implement practices to keep them from recurring,” note Tejal K. Gandhi, MD, MPH, CPPS, and Patricia McTiernan, MS, of the NPSF, writing in “A Necessary Step to Safer Care,” published online in Inside Medical Liability.
The domains where transparency must become part of routine practice include:
NPSF acknowledges there are barriers that prevent greater openness, such as the fear of litigation and concerns about damage to a provider’s or organization’s reputation when something goes wrong. However, the report points out that these fears are unfounded, according to organizations that have pursued greater transparency.
“While clinical care is an important focus for expanding openness, it is only one area of healthcare where greater transparency is needed,” the authors concluded. “If we really want to lead through learning, we must move toward greater transparency among clinicians through peer review or other mechanisms; among organizations through regional or national collaboratives; and with the public, through reporting of useful quality and safety metrics.”
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More